Pfizer has completed the acquisition of Baxter International’s vaccines portfolio. The portfolio includes NeisVac-C and FSME-IMMUN/TicoVac. Pfizer also acquired a portion of Baxter’s facility in Orth, Austria, where these vaccines are manufactured.
 
NeisVac-C helps protect against meningitis caused by group C meningococci(MenC), and FSME-IMMUN/TicoVac helps protect against tick-borne encephalitis (TBE), an infection of the brain transmitted by the bite of ticks infected with the TBE-virus.
 
“NeisVac-C and FSME-IMMUN/Ticovac are a strong fit with our vaccines business and this acquisition adds value, scale and depth to our existing portfolio of innovative vaccines,” said Susan Silbermann, president and general manager, Pfizer Vaccines. “These best-in-class products enable us to reach a broader population with vaccines that prevent infections from serious and often fatal diseases.”